ArticleNature communications2015
Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy.
Article in Nature communications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 90 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 177 citations in OpenAlex.
- Symmetric cancer spheroid-fibroblast organization revealed in 3D by high-throughput microscopy.Communications biology · 2026Article
- A novel ex vivo platform for functional evaluation of treatment responses in metastatic ovarian cancer.NPJ precision oncology · 2026Article
- Parallelized contactless microfluidic dispenser with superhydrophobic nozzles for scalable combinatorial screening.Biomicrofluidics · 2026Article
- Improving Immune Checkpoint Therapy in the Tumor Microenvironment by Targeting T Cell Metabolism.Endocrine, metabolic & immune disorders drug targets · 2026Review
- Breast cancer cell coculture induces normal lung fibroblast transition to CAFs, promoting tumor cell dormancy and therapy resistance.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Development and validation of a computational tool to predict treatment outcomes in cells from high-grade serous ovarian cancer patients.Bioengineering & translational medicine · 2025Article
- Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth.Molecular cancer therapeutics · 2025Article
- Perfusion-based ex vivo culture of frozen ovarian cancer tissues with preserved tumor microenvironment.NPJ precision oncology · 2025Article
- A Co-Culture System for Studying Cellular Interactions in Vascular Disease.Bioengineering (Basel, Switzerland) · 2024Review
- Conditional lethality profiling reveals anticancer mechanisms of action and drug-nutrient interactions.Science advances · 2024Article
- Glutathione overproduction mediates lymphoma initiating cells survival and has a sex-dependent effect on lymphomagenesis.Cell death & disease · 2024Article
- PIBF1 regulates multiple gene expression via impeding long-range chromatin interaction to drive the malignant transformation of HPV16 integration epithelial cells.Journal of advanced research · 2024Article
- Review
- GO-CRISPR: A highly controlled workflow to discover gene essentiality in loss-of-function screens.PloS one · 2024Article
- A comparative analysis of 2D and 3D experimental data for the identification of the parameters of computational models.Scientific reports · 2023Article
- Gut-specific telomerase expression counteracts systemic aging in telomerase-deficient zebrafish.Nature aging · 2023Article
- Insights into high-grade serous carcinoma pathobiology using three-dimensional culture model systems.Journal of ovarian research · 2023Review
- Cancer-associated mesothelial cell-derived ANGPTL4 and STC1 promote the early steps of ovarian cancer metastasis.JCI insight · 2023Article
- Whole Animal Feeding FLat (WAFFL): a complete and comprehensive validation of a novel, high-throughput fly experimentation system.G3 (Bethesda, Md.) · 2023Article
- Review
30 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
Abstract
The tumour microenvironment contributes to cancer metastasis and drug resistance. However, most high throughput screening (HTS) assays for drug discovery use cancer cells grown in monolayers. Here we show that a multilayered culture containing primary human fibroblasts, mesothelial cells and extracellular matrix can be adapted into a reliable 384- and 1,536-multi-well HTS assay that reproduces the human ovarian cancer (OvCa) metastatic microenvironment. We validate the identified inhibitors in secondary in vitro and in vivo biological assays using three OvCa cell lines: HeyA8, SKOV3ip1 and Tyk-nu. The active compounds directly inhibit at least two of the three OvCa functions: adhesion, invasion and growth. In vivo, these compounds prevent OvCa adhesion, invasion and metastasis, and improve survival in mouse models. Collectively, these data indicate that a complex three-dimensional culture of the tumour microenvironment can be adapted for quantitative HTS and may improve the disease relevance of assays used for drug screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.